Rich Jonathan D, Wiviott Stephen D
Cardiovascular Division, Brigham and Women's Hospital, TIMI Study Group, Boston, MA 02115, USA.
Curr Cardiol Rep. 2007 Jul;9(4):303-11. doi: 10.1007/BF02938379.
Platelets play a central role in the pathophysiology of acute coronary syndromes (ACS). Dual antiplatelet therapy has resulted in significant advances in the treatment of ACS; however, ACS remains an important cause of morbidity and mortality. Important limitations exist among the current antiplatelet agents and therefore a pressing need for the development of improved antiplatelet agents exists. Three antiplatelet agents currently under investigation (prasugrel, AZD6140, and cangrelor) in clinical trials for the treatment of ACS appear promising.
血小板在急性冠脉综合征（ACS）的病理生理学中起着核心作用。双联抗血小板治疗已使ACS的治疗取得了重大进展；然而，ACS仍然是发病和死亡的重要原因。目前的抗血小板药物存在重要局限性，因此迫切需要研发更有效的抗血小板药物。目前正在进行治疗ACS临床试验的三种抗血小板药物（普拉格雷、AZD6140和坎格雷洛）似乎很有前景。
